Objective:To learn about the clinical manifestations, laboratory test results, and prognosis of patients with acute and chronic brucellosis, and to provide a scientific basis for clinical diagnosis and treatment.Methods:A retrospective study was conducted to collect the clinical data of 776 patients with brucellosis admitted to the First Affiliated Hospital of Xinjiang Medical University from January 2013 to December 2023. The patients were divided into acute phase group and chronic phase group according to the course of disease. Their clinical manifestations, laboratory test results, and prognosis were compared and analyzed between the two groups.Results:Out of 776 patients with brucellosis, 649 were in the acute phase group and 127 were in the chronic phase group. Male accounted for 71.6% (556/776). The age was (44.91 ± 0.60) years old, mainly concentrated in the age range of 46 - 60 years old (38.0%, 295/776). Farmers were the main occupation, accounting for 58.4% (453/776). The disease occurred in all months of the year, with autumn being the peak period (33.9%, 263/776). The primary clinical manifestations were fever (64.7%, 502/776) and fatigue (40.5%, 314/776). The incidence rates of fever and fatigue in the acute phase group were higher than those in the chronic phase group [70.4% (457/649) vs. 35.4% (45/127), 42.5% (276/649) vs. 29.9% (38/127)], with statistically significant differences ( χ2 = 56.91, 7.01, P < 0.05). Complications of the osteoarticular system were the most common, accounting for 47.8% (371/776). Abnormal results of blood routine examinations were mainly characterized by decreased hemoglobin, decreased lymphocytes, and decreased white blood cells, accounting for 53.7% (417/776), 32.6% (253/776), and 22.6% (175/776), respectively. The incidence rate of decreased hemoglobin in the acute phase group was higher than that in the chronic phase group [63.5% (412/649) vs. 3.9% (5/127)], with a statistically significant difference ( χ2 = 151.49, P < 0.001). The remaining abnormal laboratory test results were mainly characterized by elevated erythrocyte sedimentation rate, elevated C-reactive protein, and elevated aspartate aminotransferase, accounting for 75.1% (583/776), 50.6% (393/776), and 39.8% (309/776), respectively. The incidence rates of elevated erythrocyte sedimentation rate and elevated aspartate aminotransferase in the acute phase group were higher than those in the chronic phase group [77.8% (505/649) vs. 61.4% (78/127), 43.3% (281/649) vs. 22.0% (28/127)], with statistically significant differences ( χ2 = 15.28, 20.02, P < 0.001). The overall positive rate of Brucella blood culture was 57.5% (446/776), and there was a statistically significant difference in blood culture between the two groups ( χ2 = 17.08, P = 0.002). The positive rate of blood culture in the acute phase group was higher than that in the chronic phase group [60.1% (390/649) vs. 44.1% (56/127)]. Ninety-four point three percent (732/776) of patients were treated with antibiotics, with rifampicin + doxycycline as the main treatment regimen (45.2%, 331/732). The median of antibiotic types used in the acute and chronic phase groups were 3 and 4, respectively. The overall incidence rate of adverse drug reactions was 3.8% (28/732). Eighty-seven point five percent (625/714) of patients improved or recovered after treatment, while 12.5% (89/714) did not recover or experienced relapse. Conclusions:The main clinical manifestations of brucellosis patients are fever and fatigue, with a higher incidence of complications in the osteoarticular system, and a better prognosis. The incidence of fever, fatigue, decreased hemoglobin, elevated erythrocyte sedimentation rate, elevated aspartate aminotransferase, and positive Brucella blood culture in patients in the acute phase are higher, and the types of antibiotics used are fewer than those in patients in the chronic phase.

Objective:To learn about the clinical manifestations, laboratory test results, and prognosis of patients with acute and chronic brucellosis, and to provide a scientific basis for clinical diagnosis and treatment.Methods:A retrospective study was conducted to collect the clinical data of 776 patients with brucellosis admitted to the First Affiliated Hospital of Xinjiang Medical University from January 2013 to December 2023. The patients were divided into acute phase group and chronic phase group according to the course of disease. Their clinical manifestations, laboratory test results, and prognosis were compared and analyzed between the two groups.Results:Out of 776 patients with brucellosis, 649 were in the acute phase group and 127 were in the chronic phase group. Male accounted for 71.6% (556/776). The age was (44.91 ± 0.60) years old, mainly concentrated in the age range of 46 - 60 years old (38.0%, 295/776). Farmers were the main occupation, accounting for 58.4% (453/776). The disease occurred in all months of the year, with autumn being the peak period (33.9%, 263/776). The primary clinical manifestations were fever (64.7%, 502/776) and fatigue (40.5%, 314/776). The incidence rates of fever and fatigue in the acute phase group were higher than those in the chronic phase group [70.4% (457/649) vs. 35.4% (45/127), 42.5% (276/649) vs. 29.9% (38/127)], with statistically significant differences ( χ2 = 56.91, 7.01, P < 0.05). Complications of the osteoarticular system were the most common, accounting for 47.8% (371/776). Abnormal results of blood routine examinations were mainly characterized by decreased hemoglobin, decreased lymphocytes, and decreased white blood cells, accounting for 53.7% (417/776), 32.6% (253/776), and 22.6% (175/776), respectively. The incidence rate of decreased hemoglobin in the acute phase group was higher than that in the chronic phase group [63.5% (412/649) vs. 3.9% (5/127)], with a statistically significant difference ( χ2 = 151.49, P < 0.001). The remaining abnormal laboratory test results were mainly characterized by elevated erythrocyte sedimentation rate, elevated C-reactive protein, and elevated aspartate aminotransferase, accounting for 75.1% (583/776), 50.6% (393/776), and 39.8% (309/776), respectively. The incidence rates of elevated erythrocyte sedimentation rate and elevated aspartate aminotransferase in the acute phase group were higher than those in the chronic phase group [77.8% (505/649) vs. 61.4% (78/127), 43.3% (281/649) vs. 22.0% (28/127)], with statistically significant differences ( χ2 = 15.28, 20.02, P < 0.001). The overall positive rate of Brucella blood culture was 57.5% (446/776), and there was a statistically significant difference in blood culture between the two groups ( χ2 = 17.08, P = 0.002). The positive rate of blood culture in the acute phase group was higher than that in the chronic phase group [60.1% (390/649) vs. 44.1% (56/127)]. Ninety-four point three percent (732/776) of patients were treated with antibiotics, with rifampicin + doxycycline as the main treatment regimen (45.2%, 331/732). The median of antibiotic types used in the acute and chronic phase groups were 3 and 4, respectively. The overall incidence rate of adverse drug reactions was 3.8% (28/732). Eighty-seven point five percent (625/714) of patients improved or recovered after treatment, while 12.5% (89/714) did not recover or experienced relapse. Conclusions:The main clinical manifestations of brucellosis patients are fever and fatigue, with a higher incidence of complications in the osteoarticular system, and a better prognosis. The incidence of fever, fatigue, decreased hemoglobin, elevated erythrocyte sedimentation rate, elevated aspartate aminotransferase, and positive Brucella blood culture in patients in the acute phase are higher, and the types of antibiotics used are fewer than those in patients in the chronic phase.

The inflammatory response is a systemic process produced by the body in response to stimulation such as infection or injury.The inflammatory response is closely related to the pathogenesis of various diseases,and plays an important role in the progression and outcome of diseases.Under normal conditions,the inflammatory response can maintain tissue homeostasis when the body is not seriously damaged.However,an uncontrolled inflammatory response that occurs when the body is subjected to more severe stimuli may often cause serious harm to the body.The termination of the ideal inflammatory response occurs after the elimination of the inflammatory stimulus.Therefore,it is particularly important to effectively modulate the extent and scope of the inflammatory response.β-arrestin 1(ARRB1)is a multifunctional regulatory protein that plays a key role in G protein-coupled receptor(GPCR)and non-GPCR-mediated signal transduction.Meanwhile,this protein also participates in the regulation of some immune cell development,differentiation and other functions.Although ARRB1 was originally thought to be a terminator of GPCR signal transduction and can inhibit the inflammatory response,recent studies suggest that its role in inflammatory responses is complex,with dual anti-inflammatory and pro-inflammatory effects.Based on this,this article reviews the relevant research on ARRB1 and the inflammatory response in recent years,focusing on the regulatory role of ARRB1 in signaling pathway transduction and immune cell development and differentiation function,as well as its mechanism of action in regulating the progression of inflammatory diseases,in order to provide new insights for the clinical precision treatment of inflammatory diseases and the screening of drug effect targets.

The inflammatory response is a systemic process produced by the body in response to stimulation such as infection or injury.The inflammatory response is closely related to the pathogenesis of various diseases,and plays an important role in the progression and outcome of diseases.Under normal conditions,the inflammatory response can maintain tissue homeostasis when the body is not seriously damaged.However,an uncontrolled inflammatory response that occurs when the body is subjected to more severe stimuli may often cause serious harm to the body.The termination of the ideal inflammatory response occurs after the elimination of the inflammatory stimulus.Therefore,it is particularly important to effectively modulate the extent and scope of the inflammatory response.β-arrestin 1(ARRB1)is a multifunctional regulatory protein that plays a key role in G protein-coupled receptor(GPCR)and non-GPCR-mediated signal transduction.Meanwhile,this protein also participates in the regulation of some immune cell development,differentiation and other functions.Although ARRB1 was originally thought to be a terminator of GPCR signal transduction and can inhibit the inflammatory response,recent studies suggest that its role in inflammatory responses is complex,with dual anti-inflammatory and pro-inflammatory effects.Based on this,this article reviews the relevant research on ARRB1 and the inflammatory response in recent years,focusing on the regulatory role of ARRB1 in signaling pathway transduction and immune cell development and differentiation function,as well as its mechanism of action in regulating the progression of inflammatory diseases,in order to provide new insights for the clinical precision treatment of inflammatory diseases and the screening of drug effect targets.

Objective:To investigate the correlations of endoscopic evaluation results with laboratory indices and clinical disease activity in Crohn disease (CD) patients with different intestinal involvement.Methods:Data of 147 patients diagnosed as having CD who visited the Department of Gastroenterology, Zhongnan Hospital of Wuhan University from July 1, 2017 to June 30, 2022 were collected retrospectively. According to the involvement of intestinal segment, patients were divided into three groups: the group with isolated small intestinal involvement ( n=55), the group with both small intestinal and large intestinal involvement ( n=48), and the group with isolated large intestinal involvement ( n=44). Correlations of endoscopic evaluation (based on CDEIS) with laboratory indices and clinical disease activity (based on Harvey-Bradshaw index) were analyzed. Results:C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) could be used for the prediction of endoscopic disease activity. The areas under curve (AUC) of receiver operator characteristic (ROC) were 0.677 (0.506-0.849) and 0.744 (0.597-0.890), respectively. In terms of determing clinical disease activity, clinical Harvey-Bradshaw index was consistent with endoscopic CDEIS score in 65.3% (96/147) patients, showing a low positive correlation ( r=0.260, P<0.05). In subgroup analysis for patients with isolated small intestinal involvement, CRP showed no predictive value for clinical disease activity [AUC (95% CI): 0.617 (0.461-0.773), P=0.148], while for endoscopic activity neither CRP nor ESR showed predictive value [AUC (95% CI): 0.537 (0.146-0.929), P=0.829; AUC (95% CI): 0.571 (0.153-0.990), P=0.680]. Furthermore, for patients with isolated small intestinal involvement and both small intestinal and large intestinal involvement, no correlation was found between clinical Harvey-Bradshaw index and endoscopic CDEIS score ( r=0.222, P=0.092; r=0.142, P=0.322). Conclusion:For CD patients with small intestinal involvement, especially isolated small intestinal involvement, laboratory indices and clinical disease activity cannot accurately reflect endoscopic disease activity. Great importance should be attached to evaluation of the extent and activity of intestinal lesions by endoscopy, especially enteroscopy.

This paper reports a case of adult-onset autoimmune enteropathy (AIE) diagnosed and treated at the Department of Gastroenterology in Zhongnan Hospital of Wuhan University. The patient had intermittent abdominal pain with diarrhea and weight loss as the main clinical manifestations. Laboratory examination results showed increased IgG and IgE, and positive antinuclear antibody (ANA) . Obvious villous atrophy of duodenum and ileum was observed under endoscopy. The intestinal biopsy showed villous atrophy of duodenum, reduction of goblet cells, lymphocyte infiltration of the lamina propria and flattening and blunting of villous of ileum mucosa. The patient was comprehensively diagnosed as AIE. Prednisone therapy is effective and the patients is being followed up closely. Adult-onset AIE is rare. Summarizing the diagnosis and treatment experience of this patient is helpful to improve clinicians′ understanding of diagnosis and differential diagnosis of AIE.

Crohn′s disease (CD) with vascular disease is difficult to distinguish from simple vascular disease and easy to misdiagnose clinically. A case of CD with vascular disease misdiagnosed as fibromuscular dysplasia is reported to improve clinicians′ understanding of the two diseases.

This paper reports a case of adult-onset autoimmune enteropathy (AIE) diagnosed and treated at the Department of Gastroenterology in Zhongnan Hospital of Wuhan University. The patient had intermittent abdominal pain with diarrhea and weight loss as the main clinical manifestations. Laboratory examination results showed increased IgG and IgE, and positive antinuclear antibody (ANA) . Obvious villous atrophy of duodenum and ileum was observed under endoscopy. The intestinal biopsy showed villous atrophy of duodenum, reduction of goblet cells, lymphocyte infiltration of the lamina propria and flattening and blunting of villous of ileum mucosa. The patient was comprehensively diagnosed as AIE. Prednisone therapy is effective and the patients is being followed up closely. Adult-onset AIE is rare. Summarizing the diagnosis and treatment experience of this patient is helpful to improve clinicians′ understanding of diagnosis and differential diagnosis of AIE.

Crohn′s disease (CD) with vascular disease is difficult to distinguish from simple vascular disease and easy to misdiagnose clinically. A case of CD with vascular disease misdiagnosed as fibromuscular dysplasia is reported to improve clinicians′ understanding of the two diseases.

Objective: To investigate the sexual function, urinary function and quality of life in patients of ulcerative colitis(UC) and familial adenomatous polyposis(FAP) after total proctocolectomy and ileal pouch anal anastomosis (IPAA). Methods: The clinical data of patients with UC and FAP undergoing IPAA at Zhongnan Hospital of Wuhan University from Jan 2006 to Sep 2018 were reviewed , postoperative sexual function, urinary function, and long-term quality of life were assessed. Results: There were 45 patients with median age of 35 years , median follow-up time of 31 months. 18 were UC, 27 were FAP, 5 did 1-stage surgery, 37 did 2-stage surgery, 3 for 3-stage surgery, 13 underwent open surgery, and 32 underwent laparoscopic surgery. 7 patients suffered sexual dysfunction after IPAA, and there was no statistical difference between male and female (P=0.992), UC and FAP (P=0.153), 1-stage , 2-stage , and 3-stage surgery (P=0.363) , with statistically significant difference between the open group and the laparoscopic group (P=0.025). 6 patients complicated with urinary dysfunction after IPAA , and there was no statistical difference between male and female (P=0.562), UC and FAP (P=0.325), 1-stage, 2-stage, and 3-stage surgery (P=0.286) , with statistically significant difference between the open group and the laparoscopic group (P=0.007). The Cleveland Global Quality of Life (CGQL) score after IPAA was 0.696±0.085. There were no statistical difference on CGQL scores in males and females (P=0.635), UC and FAP (P=0.664), 1-stage, 2-stage, and 3-stage (P>0.05), open group and laparoscopic group (P=0.205), postoperative long-term QOL was significantly associated only with age at the time of surgery (P=0.001). Conclusions Compared with open surgery, laparoscopic TPC-IPAA patients had better postoperative sexual function and urination function.